Introduction: Pakistan, Indonesia, Bangladesh and the Philippines are listed as among the six Asian countries which will be the sources of 43% or almost 4000 new cases of the estimated world’s retinoblastoma cases in 2023. Materials and Methods: Scoping review of literatures using the databases of Pubmed, EMBASE, Scopus, Science Direct, Google scholar and Web of Science databases as well as local and regional databases on clinical features, treatment and outcomes of retinoblastoma patients from Pakistan, Indonesia, Bangladesh and the Philippines was done. A descriptive analysis using the 2017 retinoblastoma database of the Global Retinoblastoma Study Group (GRSG) was added to supplement data for Bangladesh, Indonesia and the Philippines. Results: A total of 17 articles were included in this review. There were 696 retinoblastoma patients involving at least 859 eyes seen in Pakistan from 1997 to 2018 and included in the 7 articles reviewed. There were 617 retinoblastoma patients involving at least 677 eyes seen in Indonesia from 2003 to 2018 and included in the 8 articles reviewed and the GRSG’s database. There were 161 retinoblastoma patients involving 221 eyes identified in the descriptive analysis of the GRSG’s database for Bangladesh. And there were 226 retinoblastoma patients involving 297 eyes seen in the Philippines from 1998-2020 from the 2 articles from the Philippines and the GRSG’s database. Discussion: Lack of awareness on the disease, distant centers, expensive service and cultural unacceptability of treatment were the commonly cited reasons for late consult. However, non-standardized and poor clinical reporting and monitoring, and non-standardized treatment protocols were also contributory to the low survival rates. The current management outcomes of retinoblastoma from the four countries are alarmingly below par with developed countries, India and China. Conclusion: Although advances had been made in the management of retinoblastoma, delay in consultation which often leads to advanced disease was still common. This contributes to low survival rates in the four countries.
Nanoparticles are used in wide range of applications given their unique optical, chemical and electronic properties. Microbial biosynthesis of nanoparticles has offered a milder and eco-friendly alternative to physical and chemical methods of synthesis. One potential use of nanoparticles is for the inhibition of quorum sensing-mediated processes by microorganisms during pathogenic colonization and infection. In this study, bacteria from hyperalkaline spring (pH 11) were isolated using various enrichment media. The isolates, phylogenetically related to Lysinibacillus sp. and Pseudomonas stutzeri, were investigated for their ability to biosynthesize gold nanoparticles (AuNPs) via reduction of chloroauric acid (HAuCl4) at pH 9. Extracellular synthesis of gold nanoparticles was confirmed by UV-Vis absorption analysis which showed a peak at 500-600 nm wavelength range corresponding to the surface plasmon resonance of AuNPs. The AuNPs synthesized were of spherical and irregular shapes as revealed by SEM analysis. The presence of elemental gold was further confirmed by EDX analysis. FTIR results showed that various functional groups are possibly involved in the reduction of HAuCl4 and stabilization of synthesized gold nanoparticles. The inhibitory effect of biosynthesized AuNPs was tested on the growth and pyocyanin production of Pseudomonas aeruginosa PA01 during a 72-hour incubation period. Although the biosynthesized AuNPs showed no toxicity to the test organism, an increasing inhibition level of pyocyanin production was observed with increasing volumes of nanoparticles used. The levels of pyocyanin in setups treated with biosynthesized gold nanoparticles at 10, 30 and 50 L were significantly lower compared to the untreated setups (P ≤ 0.05). Our findings demonstrate that bacteria adapted to alkaline conditions can be used for efficient biosynthesis of AuNPs, which exhibited potential biomedical application in inhibiting pyocyanin production.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.